SCHEMBL2182344

SCHEMBL2182344

Cn1c(=O)c2nc(NCCN3CCOCC3)nnc2n(C2CCCC2)c1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.42
POLB P06746 2/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
MAP3K11 Q16584 1/20 0.38
RAB9A P51151 1/20 0.38
PDE5A O76074 1/20 0.38
MAPK1 P28482 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TSHR P16473 2/20 0.38
CNR2 P34972 4/20 0.38
CNR1 P21554 3/20 0.38
MAPK8 P45983 1/20 0.37
BACE1 P56817 1/20 0.37
EGFR P00533 1/20 0.37
CA12 O43570 1/20 0.37
ABL1 P00519 1/20 0.37
CA2 P00918 1/20 0.37
CA9 Q16790 1/20 0.37
HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2184055 0.94 POLB (0.48) ALDH1A1POLBMEN1KMT2AMAP3K11
SCHEMBL2182140 0.91 ADORA2A (0.37)
SCHEMBL2181800 0.90 SRC (0.36) MAPK8EGFR
SCHEMBL2181998 0.88 GAA (0.40) SMN1; SMN2CA2CA9
SCHEMBL2182586 0.85 POLB (0.51) ALDH1A1POLBMEN1KMT2AMAPK1
SCHEMBL2182971 0.85 POLB (0.39) POLBMEN1KMT2A
SCHEMBL2179278 0.84 CNR2 (0.47) ALDH1A1MEN1KMT2AMAPK1SMN1; SMN2
SCHEMBL2184891 0.84 SRC (0.41) ALDH1A1POLBMAPK8EGFR
SCHEMBL2183025 0.84 TLR9 (0.41) ALDH1A1MAP3K11PDE5ACNR2BACE1
SCHEMBL2182366 0.83 ADORA2A (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230181524-A1 PHARMACEUTICAL COMBINATION AND USE THEREOF NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) 2023-06-15 US disclosed
US-20110166144-A1 Pyrimidotriazinediones and Pyrimidopyrimidinediones and Methods of Using the Same THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2011-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230181524-A1 PHARMACEUTICAL COMBINATION AND USE THEREOF TCF4, TCF7L2, CTNNB1 ALDH1A1 1526/4885POLB 254/4885MEN1 1052/4885
US-20110166144-A1 Pyrimidotriazinediones and Pyrimidopyrimidinediones and Methods of Using the Same DPYD, TYMP, DHFR ALDH1A1 245/4885POLB 312/4885MEN1 2044/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.